Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus RAZADYNE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus RAZADYNE ER.
ADLARITY vs RAZADYNE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor